The global pharmaceutical industry could generate about $1.2 trillion in sales in 2025, according to Statista, and projections call for 4.7% annual growth through 2029. The cancer treatment segment ...

Gilead's Trodelvy and Merck's Keytruda improved progression-free survival in PD-L1+ metastatic TNBC in a Phase 3 trial with ...

Trodelvy combo improved progression-free survival in patients with PD-L1-positive tumors compared to Keytruda-chemo.

Gilead Sciences, Inc. (GILD) announced on Monday that its late-stage study showed a combination of its drug Trodelvy with ...

In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in ...

Merck is growing pharma sales and expanding margins, led by strong KEYTRUDA performance and cost discipline. Read more about ...

Gilead Sciences (GILD) announced topline results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, demonstrating that Trodelvy plus Keytruda ...

Gilead Sciences said that it saw positive results from the phase 3 study of its Trodelvy therapy in combination with Merck's Keytruda in patients with inoperable locally advanced or metastatic ...

Gilead Sciences announced significant results from a Phase 3 study of Trodelvy combined with Merck's Keytruda in treating ...

Gilead Sciences said a combination of its cancer drug Trodelvy and Merck’s Keytruda delayed the growth of tumors in women ...

Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's ...

The PD-L1 IHC 22C3 PharmDx (Code SK006) assay is now certified for use to aid treatment decisions for patients with gastric or gastroesophageal junction adenocarcinoma.